Company Overview and News
PBA Holdings Bhd (-ve) TRADING of shares in PBA Holdings Bhd (fundamental: 1.8/3, valuation: 2/3) triggered our momentum algorithm yesterday for the fifth time this year. PBA closed up two sen or 1.57% at RM1.29 with a market capitalisation of RM426.99 million, after 956,300 shares were traded, versus the counter’s 200-day average volume of 79,794.5 shares.
KUALA LUMPUR (Oct 5): AllianceDBS Research said PBA Holdings Bhd (PBA) had on Oct 4 traded higher to RM1.30 before settling at RM1.29 (up 2 sen or 1.57%).
KUALA LUMPUR (Sept 19): Vizione Holdings Bhd rose 7.14% in active trade early today after it bagged an RM89.9 million contract from PBA Holdings Bhd to build submarine pipelines from Butterworth to the Macallum area on Penang Island.
KUALA LUMPUR: Based on corporate announcements and news flow today, companies that may be in focus on Wednesday (Sept 19) may include the following: FGV Holdings Bhd, MSM Malaysia Holdings Bhd, Ideal Jacobs (M) Corp Bhd, Berjaya Food Bhd, Vizione Holdings Bhd, WCT Bhd, Damansara Realty Bhd, YFG Bhd, Telekom Malaysia Bhd, Superlon Holdings Bhd, MMAG Holdings Bhd and PanPages Bhd.
4863 7235 9679 5196 MYTEF 5041 5202 0162 BSMAF 7099 1818 3484
KUALA LUMPUR (Sept 18): Vizione Holdings Bhd has bagged a RM89.9 million contract from PBA Holdings Bhd to build submarine pipelines from Butterworth to the Macallum area on Penang Island.
5041 BSMAF 1818
KUALA LUMPUR, Sept 2 — Political patronage at state government-linked companies (GLC) practised by Barisan Nasional (BN) has continued in states controlled by the now-defunct Pakatan Rakyat and that of its former component member PAS, a recently released research showed.
GEORGE TOWN, June 28 ― The Penang state government and Penang Water Supply Corporation (PBAPP) has proposed for raw water resource management programme encompassing the northern states of the peninsula.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...